Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

lung cancer

This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.

Merck puts prostate cancer firmly in Keytruda’s sights

Merck puts prostate cancer firmly in Keytruda’s sights

Prostate cancer is the most common cancer in men, the second most prevalent after breast cancer, and a higher incidence than lung cancer, which has driven Keytruda’s sales to date. ... And while lung cancer is actually in decline in developed markets

Latest news

  • Cancer drugs and China sustain AZ’s return to growth Cancer drugs and China sustain AZ’s return to growth

    The star in oncology for AZ is non-small cell lung cancer (NSCLC) therapy Tagrisso (osimertinib), which grew 95% to $1.86bn last year, thanks to a move up the treatment ... The performance wasn’t all about cancer and China however, as other launches

  • GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

    PD-L1 expressing advanced non-small cell lung cancer (NSCLC). ... The deal with GSK sees Merck receive an upfront payment of 300m with potential development milestone payments of up to 500m triggered by data from the M7824 lung cancer programme.

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    drug that could challenge AstraZeneca’s Tagrisso in lung cancer. ... The EMA’s advisory committee gave a positive opinion on Vizimpro (dacomitinib) as a single-agent therapy for locally advanced or metastatic EGFR-positive non-small cell lung cancer

  • Analysts look beyond Keytruda in Merck’s future Analysts look beyond Keytruda in Merck’s future

    Thanks to a near-constant roll-out of new indications and its dominance of the big lung cancer market, Keytruda (pembrolizumab) brought in $2.2bn in the last quarter, a 66% ... use into new cancer types, as well as moving the drug earlier in the

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    cancer therapy Herceptin (trastuzumab) offset by gains of 14% in the US and 10% elsewhere. ... for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).

More from news
Approximately 95 fully matching, plus 700 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

  • China’s clinical trial shake-up China’s clinical trial shake-up

    For example, around 40% of new lung cancer diagnoses worldwide are in China. ... Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year. ... Value assessment. More and faster NICE appraisals for new medicines including speeding up the appraisal of

  • Is China ready for a pharmaceutical gold rush?

    With most lung cancer patients already at an advanced stage when diagnosed, prolonging survival is an important goal. ... According to Chinese Government figures, there are about 781, 000 new lung cancer diagnoses in the country every year.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The NELSON trial, which looked at screening in Europe, was presented at the recent World Conference on Lung Cancer. ... We’re starting to see that we can make the same progress in lung cancer that we’ve made in breast cancer.

More from intelligence
Approximately 1 fully matching, plus 47 partially matching documents found.

Latest appointments

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 7 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Quick links

Infographics

Multimedia